The AI Platform Rethinking How Drugs Are Discovered

Drug discovery is one of the most expensive and uncertain processes in science.

It can take over a decade and billions of dollars to bring a single drug to market. Even then, most candidates fail.

For years, the industry has tried to improve this with artificial intelligence. But most approaches still rely on finding patterns in large datasets.

MindWalk is taking a different approach.

Instead of just looking for patterns, its platform is designed to better understand how biology actually works.

MindWalk is still in the early stages of building its platform, but it is beginning to show real momentum.

Revenue has grown from approximately US$13.7 million in 2020 to around US$17.6 million more recently, supported largely by discovery programs and research collaborations.

More recently, that growth has accelerated.

In the first half of fiscal 2025, revenue increased more than 40 percent year over year, driven by expanding research activity.

Margins have also improved, with gross margins rising to roughly 58 percent, up from about 46 percent the prior year.

Following a strategic shift, the company also reported approximately US$16.5 million in cash, strengthening its balance sheet.

One of the most important parts of MindWalk’s platform is not new.

Before building artificial intelligence systems, the company spent decades working in laboratory biology, focusing on antibody discovery for pharmaceutical partners.

That work produced something extremely valuable: large, proprietary datasets built from real experiments.

Over time, thousands of antibody records were generated and tested in the lab.

Today, those datasets form the foundation of the LensAI™ platform powered by HYFT® technology.

This matters because it connects computation to reality. The system is not just trained on abstract data. It is grounded in how biology behaves in real experiments.

Most artificial intelligence systems in drug discovery are built to recognize patterns.

They look at what has worked before and try to find similar solutions.

MindWalk takes a different approach.

The easiest way to understand it is through two simple ideas.

HYFT® technology is the “brain.”
The LensAI™ platform is the interface.

HYFT® technology works behind the scenes. It looks at how biology actually functions and uses those rules to generate potential drug candidates.

The LensAI™ platform is what researchers use.

It brings everything into one place, organizing scientific research, biological data, and experimental results so researchers can explore and work with it easily.

Instead of asking, “What has worked before?” the system asks,
“What should work, based on how this biology behaves?”

That shift changes how new drug candidates are found.

A simple way to picture the process is this:

Researchers use the LensAI™ platform to find a biological “lock,” such as a protein or pathway linked to a disease.

HYFT® technology then looks at that target and determines what is needed to affect it.

From there, the platform generates possible molecular “keys” designed to interact with that lock.

These keys are not chosen because they look like existing drugs.

They are chosen because they can do the job.

This matters because, in biology, things that look different can still behave the same way.

Two molecules can look completely different, yet still interact with the same target and produce the same effect, just like two different keys can open the same lock.

Traditional approaches often search for what looks similar.

That limits discovery.

By focusing on what actually works instead, MindWalk can find entirely new types of molecules that would otherwise be missed.

This helps researchers move faster from identifying a problem to designing a potential solution.

The platform also connects to lab testing, so results can be fed back into the system and improve future discoveries over time.

This is where things become more interesting.

The LensAI™ platform powered by HYFT® technology is not designed to solve a single problem.

It is designed to generate opportunities repeatedly.

Each new dataset, experiment, and validation improves the system.

Over time, this creates a feedback loop:

New candidates are generated → tested in the lab → results improve future predictions.

As this continues, the platform becomes more productive over time.

This is not just theoretical.

MindWalk is already applying the LensAI™ platform powered by HYFT® technology across several major therapeutic areas, including:

These are some of the largest areas in global healthcare.

The same underlying system is being used to explore multiple disease categories simultaneously.

Historically, MindWalk has generated revenue through discovery partnerships and research collaborations.

That continues today.

But the strategy is expanding.

The company is building a platform that can support multiple programs at once, while also developing additional revenue streams such as software access, analytics, and long-term partnerships.

At the same time, MindWalk is developing its own internal pipeline of drug candidates using the LensAI™ platform powered by HYFT® technology.

This is an important shift.

Instead of only supporting external partners, the company can also generate and advance its own therapeutic programs.

If successful, these internally developed programs could represent significantly larger long-term value.

Artificial intelligence is becoming an important part of drug discovery.

But not all approaches are the same.

What makes MindWalk interesting is not just that it uses AI, but how it uses it.

By focusing on how biology functions, rather than only on patterns in data, the LensAI™ platform powered by HYFT® technology aims to approach discovery in a different way.

And importantly, it is not just about improving research.

It is about building a system that can generate real drug candidates across multiple major disease areas over time.